Lifesci Capital upgraded shares of OnKure Therapeutics (NASDAQ:OKUR – Free Report) to a strong-buy rating in a report released on Thursday, Zacks.com reports.
Separately, Oppenheimer started coverage on shares of OnKure Therapeutics in a research note on Thursday. They set an outperform rating and a $35.00 price target on the stock.
View Our Latest Research Report on OKUR
OnKure Therapeutics Stock Performance
OnKure Therapeutics Company Profile
Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.
Featured Stories
- Five stocks we like better than OnKure Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- What is a Secondary Public Offering? What Investors Need to Know
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
